| Literature DB >> 34943841 |
Robert Chevreau1, Hussein Ghazale1, Chantal Ripoll1, Chaima Chalfouh2, Quentin Delarue2, Anne Laure Hemonnot-Girard1, Daria Mamaeva3, Helene Hirbec1, Bernard Rothhut1, Shalaka Wahane4, Florence Evelyne Perrin5,6, Harun Najib Noristani7, Nicolas Guerout2, Jean Philippe Hugnot1.
Abstract
Ependymal cells reside in the adult spinal cord and display stem cell properties in vitro. They proliferate after spinal cord injury and produce neurons in lower vertebrates but predominantly astrocytes in mammals. The mechanisms underlying this glial-biased differentiation remain ill-defined. We addressed this issue by generating a molecular resource through RNA profiling of ependymal cells before and after injury. We found that these cells activate STAT3 and ERK/MAPK signaling post injury and downregulate cilia-associated genes and FOXJ1, a central transcription factor in ciliogenesis. Conversely, they upregulate 510 genes, seven of them more than 20-fold, namely Crym, Ecm1, Ifi202b, Nupr1, Rbp1, Thbs2 and Osmr-the receptor for oncostatin, a microglia-specific cytokine which too is strongly upregulated after injury. We studied the regulation and role of Osmr using neurospheres derived from the adult spinal cord. We found that oncostatin induced strong Osmr and p-STAT3 expression in these cells which is associated with reduction of proliferation and promotion of astrocytic versus oligodendrocytic differentiation. Microglial cells are apposed to ependymal cells in vivo and co-culture experiments showed that these cells upregulate Osmr in neurosphere cultures. Collectively, these results support the notion that microglial cells and Osmr/Oncostatin pathway may regulate the astrocytic fate of ependymal cells in spinal cord injury.Entities:
Keywords: ependyma; injury; microglia; oncostatin; regeneration; spinal cord; stem cells
Mesh:
Substances:
Year: 2021 PMID: 34943841 PMCID: PMC8699053 DOI: 10.3390/cells10123332
Source DB: PubMed Journal: Cells ISSN: 2073-4409 Impact factor: 6.600
Figure 1Bioinformatics analysis of ependymal gene expression in SCI. (A): Schematic overview of main article steps and techniques. (B): Mouse spinal cord ependymal region. Ependymal cell nuclei (thoraco-lumbar level) are stained in red with neutral red dye. Surrounding parenchyma is stained in blue with luxol fast blue. The microdissected area is delimited with black dashed lines. (C): Volcano plots of genes whose expression are dysregulated after injury in the ependymal region (fold change ≥2 or −2). Top10 up and downregulated genes are indicated. (D): Selection of Gene Ontology analysis for up- and down-regulated genes with p-values. Comprehensive gene ontology analysis is provided on Table S1.
Figure 2Immunofluorescence validation. Immunofluorescences performed on control and injured spinal cords for indicated proteins. Control immunofluorescence was performed using antibody against the synthetic DYKDDDDK TAG antigen. White arrowheads and yellow arrows show examples of positive and negative cells respectively. These images are representative of 2 independent experiments (n = 6 animals in total, 7–15 sections examined per animal). Scale bars = 10 µm.
Main post injury up- and downregulated genes.
|
| ||||
|
|
|
|
|
|
|
| crystallin. mu | 33.3 | 1.6 × 10−8 | 2.5 × 10−5 |
|
| oncostatin M receptor | 30.3 | 2.6 × 10−10 | 1.7 × 10−6 |
|
| retinol binding protein 1. cellular | 28.8 | 1.8 × 10−7 | 0.0001 |
|
| nuclear protein transcription regulator 1 | 26 | 2.2 × 10−6 | 0.0006 |
|
| thrombospondin 2 | 25.8 | 3.8 × 10−12 | 5.6 × 10−8 |
|
| extracellular matrix protein 1 | 24.1 | 4.5 × 10−10 | 2.2 × 10−6 |
|
| interferon activated gene 202B; | 22.8 | 2.6 × 10−7 | 0.0001 |
|
| CCAAT/enhancer binding protein (C/EBP). delta | 15.4 | 1.0 × 10−5 | 0.0017 |
|
| tissue inhibitor of metalloproteinase 1 | 15.3 | 8.1 × 10−10 | 2.7 × 10−6 |
|
| suppressor of cytokine signaling 3 | 14.4 | 5.1 × 10−8 | 5.2 × 10−5 |
|
| olfactomedin-like 3 | 13.3 | 1.7 × 10−10 | 1.3 × 10−6 |
|
| glial fibrillary acidic protein | 12.9 | 9.8 × 10−7 | 0.0004 |
|
| FBJ osteosarcoma oncogene | 12.7 | 1.1 × 10−7 | 8.4 × 10−5 |
|
| ets variant 5 | 12.6 | 3.1 × 10−10 | 1.8 × 10−6 |
|
| serine peptidase inhibitor. clade G. member 1 | 12.2 | 9.6 × 10−9 | 1.8 × 10−5 |
|
| pentraxin related gene | 12.2 | 9.4 × 10−7 | 0.0004 |
|
| fibroblast growth factor receptor-like 1 | 11.9 | 5.5 × 10−8 | 5.5 × 10−5 |
|
| versican | 11.6 | 2.9 × 10−5 | 0.003 |
|
| S100 calcium binding protein A6 (calcyclin) | 11.3 | 0.0006 | 0.0265 |
|
| serine peptidase inhibitor. clade A. member 3N | 11.3 | 4.2 × 10−9 | 1.1 × 10−5 |
|
| predicted gene. 42151 | 11.1 | 8.2 × 10−10 | 2.7 × 10−6 |
|
| lectin. galactose binding. soluble 1 | 11.1 | 2.0 × 10−6 | 0.0006 |
|
| fibrinogen-like protein 2 | 10.7 | 1.4 × 10−8 | 2.2 10−5 |
|
| guanylate binding protein 3 | 10.1 | 0.017 | 0.23 |
|
| ||||
|
|
|
|
|
|
|
| actin. alpha 1. skeletal muscle | −21.2 | 0.035 | 0.35 |
|
| proprotein convertase subtilisin/kexin type 2 | −7.4 | 1.3 × 10−6 | 0.0004 |
|
| synuclein. alpha | −5.8 | 0.0009 | 0.036 |
|
| myosin. heavy polypeptide 1. skeletal muscle. adult | −5.3 | 0.007 | 0.13 |
|
| synuclein. alpha | −5.2 | 0.018 | 0.24 |
|
| trichohyalin | −4.7 | 0.0005 | 0.027 |
|
| myosin. heavy polypeptide 1. skeletal muscle. adult | −4.7 | 0.007 | 0.137 |
|
| chromodomain helicase DNA binding protein 3. opposite strand | −4.6 | 1.5 × 10−5 | 0.0021 |
|
| myoglobin | −4.6 | 0.0001 | 0.008 |
|
| Semaphorin 5A | −4.4 | 0.015 | 0.22 |
|
| small nucleolar RNA host gene 11 | −4.4 | 0.006 | 0.11 |
|
| coiled-coil domain containing 108 | −4.2 | 3.5 × 10−6 | 0.0008 |
|
| troponin I. skeletal. fast 2 | −4.1 | 0.02 | 0.254 |
|
| phospholipid phosphatase related 4 | −4.1 | 3.3 × 10−5 | 0.004 |
|
| calsyntenin 2 | −4.1 | 0.002 | 0.05 |
|
| troponin I. cardiac 3 | −4.0 | 6.6 × 10−5 | 0.006 |
|
| acyl-CoA synthetase long-chain family member 3 | −4.0 | 0.019 | 0.25 |
Figure 3Spinal cord organotypic slice cultures. Immunofluorescences for indicated proteins performed on spinal cord slices after collection (Day 0) and after 3 days in culture (Day 3). White arrowheads and yellow arrows show examples of positive and negative cells respectively. These images are representative of 3 independent experiments. (n = 4 animals, 5 sections examined per culture). Scale bars = 10 µm.
Figure 4Cilia gene expression is affected by SCI and culture conditions. (A): Microarray quantifications of indicated genes in control vs injured spinal cord ependyma and growing spinal cord neurospheres (n = 6 for spinal cords and n = 4 for neurosphere cultures). Tests = one way ANOVA with Tukey post-hoc tests. Values represent fold changes compared to control spinal cords. (B): Microarray quantifications of indicated genes in neurospheres cultured in 3 conditions (n = 4 for each conditions): with EF (i.e., growing with EGF and FGF2), w/o EF (i.e., differentiated by removing EGF and FGF2), and re EF (reintroduction of EGF and FGF2 for 3 days after the differentiation step). Tests = one way ANOVA with Tukey post-hoc tests. Values represent fold change compared to neurospheres in the growing condition. ***, p < 0.001; **, p < 0.01; *, p ≤ 0.05. n.s. = not significant.
Figure 5OSM affects OSMR expression, neurosphere growth and differentiation. (A): Left-hand images: immunofluorescences for FOXJ1 in spinal cord neurosphere cells cultured in proliferation (with growth factors) or differentiation (without growth factors) conditions. Scale bar = 10 µm. Right panels: immunofluorescence quantification (n = 7 fields). (B): Left-hand panel: WB for OSMR on proteins extracted from control and injured total spinal cord (3 and 5 days post injury). Proteins were extracted from spinal cord segments containing and adjacent to the lesion site. β-actin was used for normalization. Right-hand panel: WB quantification. Values represent fold change compared to uninjured spinal cord protein extracts. Tests = one way ANOVA with Tukey post-hoc tests. n = 3 independent experiments. (C): QPCR for Osmr RNA in growing spinal cord neurospheres treated for 3 days with indicated cytokines. Values represent fold change compared to untreated neurospheres. Statistical tests were performed with Bootstratio [23] compared to non-treated neurospheres. n = 3 independent experiments. (D): Left-hand panels: immunofluorescences for OSMR in control or OSM-treated spinal cord neurosphere cells. Scale-bar = 10 µm. Right-hand panel: immunofluorescence quantification (n = 10 fields). Test = two tailed t-test. Lower panel. WB for OSMR on proteins extracted from untreated and OSM-treated neurospheres. Numbers represent quantification (fold change) compared to untreated neurospheres. β-actin was used for normalization. (E): Left-hand panels: immunofluorescences for p-STAT3 (phospho-STAT3) in control or OSM-treated spinal cord neurosphere cells. Scale-bar = 10 µm. Right-hand panel: immunofluorescence quantification (n = 6 fields). Test = two tailed t-test. Lower panel. WB for p-STAT3 on proteins extracted from untreated and OSM-treated neurospheres. Numbers represent quantification (fold change) compared to untreated neurospheres. β-actin is used for normalization. (F): Left panels: Immunofluorescence for GFAP in untreated and OSM-treated neurosphere cell cultures. Right-hand panel: immunofluorescence quantification (n = 10 fields). Test = two tailed t-test. Lower panel: WB for GFAP on proteins extracted from untreated and OSM-treated neurospheres. Numbers represent quantification (fold change) compared to untreated neurospheres. β-actin is used for normalization. (G): Effect of OSM on neurosphere growth. Left-hand panel: Diagram shows the number of cells obtained in untreated and OSM-treated neurospheres 6 days after seeding (n = 8 wells). Test = two tailed t-test. Right-hand panel: Diagram shows the % of MKI67+ cells obtained in untreated and OSM-treated cell cultures (n = 10 fields). Test = two tailed t-test. (H): Effect of OSM on spinal cord stem cell differentiation. Diagram shows the % of GFAP+ and OLIG1+ cells, 4 days after differentiation in untreated and OSM-treated cell cultures. Tests = Mann-Whitney tests, n = 5 independent experiments. ***, p < 0.001; **, p < 0.01; *, p ≤ 0.05. n.s. = not significant. IF = immunofluorescence.
Figure 6Microglia upregulate OSMR expression in spinal cord neurosphere cells. (A): QPCR for indicated cytokines in RNA extracted in sham-operated and injured spinal cord (3 days after SCI). n = 3 independent experiments. Numbers indicate the fold change compared to sham-operated spinal cords. Statistical tests were performed with Bootstratio (Clèries et al., 2012) compared to control spinal cords. (B): Immunofluorescences for GFP performed in CX3CR1+/GFP mice to reveal microglia (green) associated with ependymal cells. White arrowheads and arrows show microglia somas and processes respectively, close or within the ependymal cell layer. Scale bars = 10 µm. (C): Left-hand panel: detection of the OSM cytokine in the supernatant of BV-2 microglial cell culture by ELISA (n = 4 independent experiments). Right-hand panel: detection of indicated cytokines in BV-2 microglia by QPCR (n = 3 independent experiments). (D): Influence of BV-2 cells on OSMR expression in spinal cord neurosphere cells. Left-hand panel: QPCR for OSMR. RNA were extracted from GFP+ spinal cord neurosphere cells cultured without (control) and with BV-2 cells. Values represent fold change compared to control neurospheres. Statistical test was performed with Bootstratio (Clèries et al., 2012) compared to control neurospheres. n = 3 independent experiments. Lower panel: Immunofluorescences for OSMR in GFP+ spinal cord neurosphere cells cultured without (control) or with BV-2 microglia. Scale bars = 10 µm. Right-hand panel: Quantification of immunofluorescences (n = 6 fields). test= two tailed t-test. (E): Influence of BV-2 cells on GFAP expression in spinal cord neurosphere cells. Left-hand panel: QPCR for GFAP. RNA were extracted from spinal cord neurosphere cells cultured without (control) and with BV-2 cells. Values represent fold change compared to control neurospheres. Statistical test was performed with Bootstratio (Clèries et al., 2012) compared to control neurospheres. n = 3 independent experiments. Lower panel: Immunofluorescences for GFAP in GFP+ spinal cord neurosphere cells cultured without (control) or with BV-2 microglia. Scale bars = 10 µm. Right-hand panel: Quantification of immunofluorescences (n = 10 fields). test= two tailed t-test. ***, p < 0.001; **, p < 0.01; *, p ≤ 0.05. n.s. = not significant. IF = immunofluorescence.